Detalles de la búsqueda
1.
Evaluation of cardiac parameters and other safety outcomes of brolucizumab treatment in patients with neovascular age-related macular degeneration.
Pharmacol Res Perspect
; 10(2): e00897, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35301822
2.
KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema.
Am J Ophthalmol
; 238: 157-172, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35038415
3.
Effects of the Dual Endothelin Receptor Antagonist Aprocitentan on Body Weight and Fluid Homeostasis in Healthy Subjects on a High Sodium Diet.
Clin Pharmacol Ther
; 109(3): 746-753, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32897570
4.
Lucerastat, an Iminosugar for Substrate Reduction Therapy: Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Fabry Disease on Enzyme Replacement.
Clin Pharmacol Ther
; 103(4): 703-711, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28699267
5.
Lucerastat, an Iminosugar for Substrate Reduction Therapy: Pharmacokinetics, Tolerability, and Safety in Subjects With Mild, Moderate, and Severe Renal Function Impairment.
J Clin Pharmacol
; 57(11): 1425-1431, 2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-28618006
6.
Effect of Hepatic or Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Ponesimod, a Selective S1P1 Receptor Modulator.
Basic Clin Pharmacol Toxicol
; 118(5): 356-68, 2016 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-26525450
7.
Analysis of unipolar electrograms in rabbit heart demonstrated the key role of ventricular apicobasal dispersion in arrhythmogenicity.
Cardiovasc Toxicol
; 14(4): 316-28, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24740433
Resultados
1 -
7
de 7
1
Próxima >
>>